肿瘤复杂性与技术对经皮微波消融治疗T1a期肾细胞癌疗效及并发症的影响:单中心回顾性研究
本单中心回顾性研究纳入96例患者共100个活检证实的T1a期肾细胞癌,评估肿瘤复杂性及技术因素对经皮微波消融早期和中期肿瘤学疗效及并发症率的影响。技术成功率为100%,3年局部无进展生存率88%、癌症特异性生存率100%、总生存率91%,结论认为经皮微波消融是T1a期肾细胞癌有效且安全的治疗选择,无论肿瘤复杂性如何,但需长期随访以确立持久疗效。
要点
- 100个T1a期肾细胞癌经皮微波消融技术成功率达100%,包括47个中度复杂和5个高度复杂肿瘤。
- 3年局部无进展生存率88%、癌症特异性生存率100%、总生存率91%,仅1例(1%)出现局部肿瘤进展。
- 手术相关并发症3例(3%),延迟并发症6例(6%)均为尿性囊肿,术后估算肾小球滤过率无显著变化(P = .49)。
核心结论
- 经皮微波消融是T1a期肾细胞癌有效且安全的治疗选择,无论肿瘤复杂性如何;需长期随访以确立相对于其他消融方式和手术的持久肿瘤学疗效和生存。
研究设计与样本
- HIPAA合规的单中心回顾性研究,经机构审查委员会批准并豁免知情同意;纳入2011年3月至2015年6月间96例连续患者(68男、28女,平均年龄66岁±9.4)共100个活检证实的T1a N0M0期肾细胞癌(中位直径2.6 cm±0.8),均接受经皮微波消融。
诊断标准与关键数值
- 技术成功定义为全部100个肿瘤(100%)完成消融,包括47个中度复杂和5个高度复杂肾细胞癌;中位临床随访17个月(范围0-48个月),中位影像随访15个月(范围0-44个月);3年局部无进展生存率88%(95%CI:0.52%,0.97%),癌症特异性生存率100%(95%CI:1.0%,1.0%),总生存率91%(95%CI:0.51%,0.99%)。
临床应用与阅片要点
- 原文结论认为经皮微波消融是T1a期肾细胞癌有效且安全的治疗选择,无论肿瘤复杂性如何;原文指出需长期随访以确立持久肿瘤学疗效和生存。
局限性
- 原文结论指出需长期随访以确立相对于其他消融方式和手术的持久肿瘤学疗效和生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the effects of tumor complexity and technique on early and midterm oncologic efficacy and rate of complications for 100 consecutive biopsy-proved stage T1a renal cell carcinomas (RCCs) treated with percutaneous microwave ablation. Materials and Methods This HIPAA-compliant, single-center retrospective study was approved by the institutional review board. The requirement to obtain informed consent was waived. Ninety-six consecutive patients (68 men, 28 women; mean age, 66 years ± 9.4) with 100 stage T1a N0M0 biopsy-proved RCCs (median diameter, 2.6 cm ± 0.8) underwent percutaneous microwave ablation between March 2011 and June 2015. Patient and procedural data were collected, including body mass index, comorbidities, tumor histologic characteristics and grade, RENAL nephrometry score, number of antennas, generator power, and duration of ablation. Technical success, local tumor progression, and presence of complications were assessed at immediate and follow-up imaging. The Kaplan-Meier method was used for survival analyses. Results Technical success was achieved for all 100 tumors (100%), including 47 moderately and five highly complex RCCs. Median clinical and imaging follow-up was 17 months (range, 0-48 months) and 15 months (range, 0-44 months), respectively. No change in estimated glomerular filtration rate was noted after the procedure (P = .49). There were three (3%) procedure-related complications and six (6%) delayed complications, all urinomas. One case of local tumor progression (1%) was identified 25 months after the procedure. Three-year local progression-free survival, cancer-specific survival, and overall survival were 88% (95% confidence interval: 0.52%, 0.97%), 100% (95% confidence interval: 1.0%, 1.0%), and 91% (95% confidence interval: 0.51%, 0.99%), respectively. Conclusion Percutaneous microwave ablation is an effective and safe treatment option for stage T1a RCC, regardless of tumor complexity. Long-term follow-up is needed to establish durable oncologic efficacy and survival relative to competing ablation modalities and surgery. © RSNA, 2017.
引用
- Klapperich ME, Abel EJ, Ziemlewicz TJ, et al. Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology. 2017. PMID: 28076721. doi:10.1148/radiol.2016160592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。